复合TCI异丙酚时瑞芬太尼抑制支撑喉镜诱发心血管反应的EC50

Objective To determine the median effective concentration(EC50) of remifentanil by TCI inhibiting the cardiovascular response to the placement of operating laryngoscope performed under propofol anesthesia administered by TCI.Methods Twenty ASA Ⅰ orⅡ patients,aged 20-51 yr,weighing 52-83 kg,undergoing extirpation of vocal cord polyps under general anesthesia with remifentanil-pmpofol administered by TCI.were enrolled in the study.The target plasma concentration (Cp) of propofol was set at 4μg/ml.Operating laryngoscope was placed at 3 min after tracheal intubation.HR and MAP were continuously monitored.When HR or MAP increased by 15%,the candiovascular response was defined as positive.The EC50 was determined by up-and-down technique.The initial Cp of remifentanil was set at 5 ng/ml and was increased/decreased by 20%in the next patient if the cardiovascular response was positive or negative.Results No chest wall stiffness and intraoperative awareness occurred in all the patients.The EC50 of remifentanil TCI inhibiting the cardiovascular response to the placement of operating laryngoscope was 3.50ng/ml with confidence interval(CI) between 3.47-3.60 ng/ml.Conclusion Thee EC50 of remifentanil TCI inhibiting cardiovascular response to the placement of operating laryngoscope is 3.50ng/ml with CI between 3.47-3.60ng/ml.     

靶控输注瑞芬太尼和异丙酚麻醉诱导时镇静催眠效应的相互作用

Objective To investigate the sedative and hypnotic interaction between remifentanil and propofol by target-controlled infusion (TCI) during induction of anesthesia.Methods Third-two ASA Ⅰ or Ⅱpatients,aged 22-63 yr,body mass index 18-25 kg/m2,scheduled for elective surgery under general anesthesia,were randomly divided into 4 groups(n=8 each).Group Ⅰ only received TCI pmpofol.GroupⅡ,Ⅲ,and Ⅳreceived a target concentration of 2,4 or 6 ng/ml remifentanil respectively.While the blood-effect site concentrations of remifentanil were equilibrated,patients received TCI of propefol,with an initial target concentration of 0.5μg/ml.After the blood-effect site concentrations of propofol were equilibrated then with 0.5μg/ml increments until the loss consciousness was achieved.The eyelash reflex and state of consciousness were assessed and radial arterial blood sample 6 ml was taken every 3 min to determine the remifentanil and propofol concentrations in blood.Propofol and remifentanil concentrations in blood were measured by reversed-phase high-performance liquid chromatography and high-performance liquid chromatography with ultraviolet detection respectively.The sedative and hypnotic interaction between propofol and remifentanil was determined with a pharmacodynamie interaction model by regression analysis and determined using the isobolographic method.Results Propofol concentrations in blood were lower in group Ⅱ,Ⅲ and Ⅳ than group Ⅰ(P<0.05).The propofol concentratopms in blood were significantly decreased in trun with the increase in the remifentanil concentrations in blood in group Ⅱ-Ⅳ(P<0.05).At loss of eyelash reflex and loss of consciousness of patients,the pharmacodynamic interaction model by curve fitting was superior to linear regression (P<0.05).At loss of eyelash reflex of patients,the curve fitting result showed EC50,prop=2.77μg/ml and EC50,rem=26.67 ng/ml,and the isobolographic method equation is ECprop/2.77+ECrem/26.67=0.69.At loss of consciousness of patients,the curve fitting result showed EC50,prop==3.76μg/ml and EC50,rem=31.56ng/ml,and the isobolographic method equation is Ecprop/3.76+Ecrem/31.56=0.65.Conclusion Remifentanil (Cp 2-6 ng/ml) and propofol by TCI shows a synergistic type of pharmacodynamic interaction on the sedative and hypnotic during induction of anesthesia.     

靶控输注瑞芬太尼和异丙酚麻醉诱导时镇静催眠效应的相互作用

Objective To investigate the sedative and hypnotic interaction between remifentanil and propofol by target-controlled infusion (TCI) during induction of anesthesia.Methods Third-two ASA Ⅰ or Ⅱpatients,aged 22-63 yr,body mass index 18-25 kg/m2,scheduled for elective surgery under general anesthesia,were randomly divided into 4 groups(n=8 each).Group Ⅰ only received TCI pmpofol.GroupⅡ,Ⅲ,and Ⅳreceived a target concentration of 2,4 or 6 ng/ml remifentanil respectively.While the blood-effect site concentrations of remifentanil were equilibrated,patients received TCI of propefol,with an initial target concentration of 0.5μg/ml.After the blood-effect site concentrations of propofol were equilibrated then with 0.5μg/ml increments until the loss consciousness was achieved.The eyelash reflex and state of consciousness were assessed and radial arterial blood sample 6 ml was taken every 3 min to determine the remifentanil and propofol concentrations in blood.Propofol and remifentanil concentrations in blood were measured by reversed-phase high-performance liquid chromatography and high-performance liquid chromatography with ultraviolet detection respectively.The sedative and hypnotic interaction between propofol and remifentanil was determined with a pharmacodynamie interaction model by regression analysis and determined using the isobolographic method.Results Propofol concentrations in blood were lower in group Ⅱ,Ⅲ and Ⅳ than group Ⅰ(P<0.05).The propofol concentratopms in blood were significantly decreased in trun with the increase in the remifentanil concentrations in blood in group Ⅱ-Ⅳ(P<0.05).At loss of eyelash reflex and loss of consciousness of patients,the pharmacodynamic interaction model by curve fitting was superior to linear regression (P<0.05).At loss of eyelash reflex of patients,the curve fitting result showed EC50,prop=2.77μg/ml and EC50,rem=26.67 ng/ml,and the isobolographic method equation is ECprop/2.77+ECrem/26.67=0.69.At loss of consciousness of patients,the curve fitting result showed EC50,prop==3.76μg/ml and EC50,rem=31.56ng/ml,and the isobolographic method equation is Ecprop/3.76+Ecrem/31.56=0.65.Conclusion Remifentanil (Cp 2-6 ng/ml) and propofol by TCI shows a synergistic type of pharmacodynamic interaction on the sedative and hypnotic during induction of anesthesia.     

靶控输注异丙酚复合瑞芬太尼麻醉时NI与BIS监测镇静深度的比较

Objective To compare bispectral index (BIS) with narcotrend index (NI) during propofol-remifentanil anesthesia administered by target-controlled infusion (TCI).Methods Ten ASA Ⅰ or Ⅱ pafients aged 18-56 yr weighing 52-67kg undergoing abdominal surgery lasting>1h were included in this study.BIS and NI were monitored simultaneously.Anesthesia was induced with TCI of propofol with target plasma concentration (Cp) of 3～4μg/ml and remifentanil (Cp 3-4ng/ml).Tracheal intubation was facilitated with cis-atracurium 0.3 mg/kg.The patients were mechanically ventilated.PETCO2 was maintained between 30-35 mm Hg.Anesthesia was maintained with TCI of propofol and remifentanil by the anesthesiologist bhnded to BIS and NI values.according to hemedynamic parameters.BIS and narcotrend values were recorded every minute and compared by another anesthesiologist.All data were compared by Bland-Altman analysis and with Kappa coefficient for agreement.The correlation between BIS and NI was tested by Spearman correlation analysis.The number of error ofjudgement (Type Ⅰ was defined as BIS<40 and NI>62;Type Ⅱ was defined as BIS>60 and NI<20)Was counted.Results The correlation and agreement between BIS and NI during maintenance of propofol-remifentanil anesthesia administered by TCI showed good consistency.Conclusion Both NI and BIS Can help anesthesiologist control the depth of anesthesia during TCI of propofol-remifentanil.     

靶控输注异丙酚复合瑞芬太尼麻醉时NI与BIS监测镇静深度的比较

Objective To compare bispectral index (BIS) with narcotrend index (NI) during propofol-remifentanil anesthesia administered by target-controlled infusion (TCI).Methods Ten ASA Ⅰ or Ⅱ pafients aged 18-56 yr weighing 52-67kg undergoing abdominal surgery lasting>1h were included in this study.BIS and NI were monitored simultaneously.Anesthesia was induced with TCI of propofol with target plasma concentration (Cp) of 3～4μg/ml and remifentanil (Cp 3-4ng/ml).Tracheal intubation was facilitated with cis-atracurium 0.3 mg/kg.The patients were mechanically ventilated.PETCO2 was maintained between 30-35 mm Hg.Anesthesia was maintained with TCI of propofol and remifentanil by the anesthesiologist bhnded to BIS and NI values.according to hemedynamic parameters.BIS and narcotrend values were recorded every minute and compared by another anesthesiologist.All data were compared by Bland-Altman analysis and with Kappa coefficient for agreement.The correlation between BIS and NI was tested by Spearman correlation analysis.The number of error ofjudgement (Type Ⅰ was defined as BIS<40 and NI>62;Type Ⅱ was defined as BIS>60 and NI<20)Was counted.Results The correlation and agreement between BIS and NI during maintenance of propofol-remifentanil anesthesia administered by TCI showed good consistency.Conclusion Both NI and BIS Can help anesthesiologist control the depth of anesthesia during TCI of propofol-remifentanil.     

舒芬太尼复合TCI异丙酚抑制前列腺电切术老年患者尿道镜置入反应的半数有效效应室靶浓度

目的 确定舒芬太尼复合TCI异丙酚抑制经尿道前列腺电切术(TURP)老年患者尿道镜置入反应的半数有效效应室靶浓度(EC50).方法 拟行TURP的患者22例,年龄65～79岁,体重47～81 kg,ASA分级Ⅰ～Ⅲ级.TCI异丙酚,血浆靶浓度4 μg/ml,异丙酚达到靶浓度后开始TCI舒芬太尼;采用序贯法,按照患者是否发生尿道镜置入反应确定舒芬太尼的效应室靶浓度,初始效应室靶浓度为0.3 ng/ml,相邻浓度比值为1.1.计算舒芬太尼的EC50及其95%可信区间.结果 舒芬太尼抑制尿道镜置入反应的EC50为0.23 ng/ml,95%可信区间为0.12～0.44 ng/ml.结论 复合TCI异丙酚(血浆靶浓度4 μg/ml)时,舒芬太尼抑制TURP老年患者尿道镜置入反应的EC50为0.23 ng/ml.

Abstract：

Objective To determine the half-effective target effect-site concentration (EC50 ) of sufentanil inhibiting the urethroscope insertion response when combined with propofol by target-controlled infusion (TCI) in the elderly patients undergoing transurethral resection of prostate (TURP) . Methods Twenty-two ASA Ⅰ- Ⅲ patients, aged 65 -79 yr, weighing 47-81 kg, undergoing TURP, were enrolled in the study. Anesthesia was performed with TCI of propofol and sufentanil. The target plasma concentration of propofol was 4 μg/ml. The target effect-site concentration of sufentanil was determined by up-and-down sequential trial. The initial target effect-site concentration of sufentanil was 0.3 ng/ml and the ratio of the target concentrations between the two consecutive patients was 1.1. The ECW and 95% confidence interval of sufentanil required to inhibit the response to urethroscope insertion were calculated. Results The EC50 of sufentanil required to inhibit the urethroscope insertion response was 0.23 ng/ml (95% confidence interval 0.12-0.44 ng/ml). Conclusion When combined with propofol by TCI (target plasma concentration 4 μg/ml), the EC50 of sufentanil inhibiting the response to urethroscope insertion is 0,23 ng/ml in the elderly patients undergoing TURP.     

不同效应室靶浓度瑞芬太尼对患者意识消失和伤害性刺激诱发体动反应消失时依托咪酯半数有效浓度的影响

Objective To investigate the effect of different target effect-site concentrations (Ces) ofremifentanil on the median effective concentration (EC50 ) of etomidate required for loss of consciousness and disappearance of nociceptive stimuli-induced body movement. Methods Eighty ASA Ⅰ orⅡ patients aged 18-64 yr scheduled for elective gynecological surgery under general anesthesia were randomly divided into 4 groups ( n = 20 each): group R0 received no remifentanil and R1-3 groups received remifentanil at 3 predetermined target Ces of 1,2 and 3 ng/ml respectively. At the beginning of anesthesia induction, remifentanil was given by target-controlled infusion (TCI) until the predetermined Ces were achieved, TCI of etomidate was then started at a target plasma concentration of 0.6 μg/ml and then the target plasma concentration of etomidate increased by 0.1 μg/ml every 1 min until the patients lost consciousness and the body movement induced by the nociceptive stimuli disappeared. The Ce of etomidate required for loss of consciousness and disappearance of nociceptive stimuli-induced body move-ment was recorded and the EC50 was calculated by Probit method. Results With the increase in the target Ces of remifentanil, the EC50 of etomidate required for loss of consciousness and disappearance of nociceptive stimuli-induced body movement decreased gradually (P < 0.05) .Conclusion Remifentanil given by TCI can enhance the sedative and analgesic effect of etomidate concentration-dependently.     

不同效应室靶浓度瑞芬太尼对患者意识消失和伤害性刺激诱发体动反应消失时依托咪酯半数有效浓度的影响

Objective To investigate the effect of different target effect-site concentrations (Ces) ofremifentanil on the median effective concentration (EC50 ) of etomidate required for loss of consciousness and disappearance of nociceptive stimuli-induced body movement. Methods Eighty ASA Ⅰ orⅡ patients aged 18-64 yr scheduled for elective gynecological surgery under general anesthesia were randomly divided into 4 groups ( n = 20 each): group R0 received no remifentanil and R1-3 groups received remifentanil at 3 predetermined target Ces of 1,2 and 3 ng/ml respectively. At the beginning of anesthesia induction, remifentanil was given by target-controlled infusion (TCI) until the predetermined Ces were achieved, TCI of etomidate was then started at a target plasma concentration of 0.6 μg/ml and then the target plasma concentration of etomidate increased by 0.1 μg/ml every 1 min until the patients lost consciousness and the body movement induced by the nociceptive stimuli disappeared. The Ce of etomidate required for loss of consciousness and disappearance of nociceptive stimuli-induced body move-ment was recorded and the EC50 was calculated by Probit method. Results With the increase in the target Ces of remifentanil, the EC50 of etomidate required for loss of consciousness and disappearance of nociceptive stimuli-induced body movement decreased gradually (P < 0.05) .Conclusion Remifentanil given by TCI can enhance the sedative and analgesic effect of etomidate concentration-dependently.     

新辅助化疗对乳腺癌患者靶控输注异丙酚意识消失时半数有效效应室靶浓度的影响

Objective To investigate the effect of neoadjuvant chemotherapy on EC50 of propofol given by TCI which produces loss of consciousness (LOC) in breast cancer patients.Methods Ninety ASA Ⅰ or Ⅱ breast cancer patients aged 30-60 yr scheduled for elective surgery were allocated into 3 groups according to the chemotherapy the patients received (n=30 each):group Ⅰ control (group C) received no chemotherapy;group Ⅱ taxol and group Ⅲ adriamycine+cyclophosphamide+5-Fu.The patients were unpremedicated.The EC50 of propofol given by TCI was determined by up-and-down technique.The initial effect-site concentration (Ce) of propofol was 2.07μg/ml and the ratio between the 2 successive Ce was 1.09.Loss of response to verbal command and eyelash stimulation was used as sighs of LOC.The EC50 of propofol was calculated.Results The EC50 of propofol causing LOC was significantly lower in group Ⅱ and Ⅲ than in control group.There was no significant difference in the EC50 of propofol which produces LOC between group Ⅱ and Ⅲ.Conclusion The EC50 of propofol causing LOC in breast cancerpatients is decreased by adjuvant chemotherapy.     

新辅助化疗对乳腺癌患者靶控输注异丙酚意识消失时半数有效效应室靶浓度的影响

Objective To investigate the effect of neoadjuvant chemotherapy on EC50 of propofol given by TCI which produces loss of consciousness (LOC) in breast cancer patients.Methods Ninety ASA Ⅰ or Ⅱ breast cancer patients aged 30-60 yr scheduled for elective surgery were allocated into 3 groups according to the chemotherapy the patients received (n=30 each):group Ⅰ control (group C) received no chemotherapy;group Ⅱ taxol and group Ⅲ adriamycine+cyclophosphamide+5-Fu.The patients were unpremedicated.The EC50 of propofol given by TCI was determined by up-and-down technique.The initial effect-site concentration (Ce) of propofol was 2.07μg/ml and the ratio between the 2 successive Ce was 1.09.Loss of response to verbal command and eyelash stimulation was used as sighs of LOC.The EC50 of propofol was calculated.Results The EC50 of propofol causing LOC was significantly lower in group Ⅱ and Ⅲ than in control group.There was no significant difference in the EC50 of propofol which produces LOC between group Ⅱ and Ⅲ.Conclusion The EC50 of propofol causing LOC in breast cancerpatients is decreased by adjuvant chemotherapy.     

复合TCI异丙酚时瑞芬太尼抑制支撑喉镜诱发心血管反应的EC50

目的 探讨复合TCI异丙酚时瑞芬太尼抑制支撑喉镜诱发心血管反应的半数有效血浆靶浓度(EC50).方法 择期拟行全麻下声带息肉摘除术患者20例,ASAⅠ或Ⅱ级,年龄20～51岁,体重52～83 kg,TCI瑞芬太尼和异丙酚行麻醉诱导,异丙酚血浆靶浓度4μg/ml,瑞芬太尼血浆靶浓度采用序贯法确定,第1例患者瑞芬太尼的血浆靶浓度5ng/ml,相邻靶浓度之比为1.2,以HR或MAP变化幅度超过基础状态15%为心血管反应阳性的判断标准.气管插管后3 min置人支撑喉镜.计算瑞芬太尼抑制支撑喉镜诱发心血管反应的EC50及其95%可信区间(CI).结果 所有患者均未见胸壁僵硬,均未发生术中知晓.瑞芬太尼抑制支撑喉镜诱发心血管反应的EC50为3.50 ng/ml,95%CI为3.47～3.60 ng/ml.结论 复合TCI异丙酚4μg/ml时瑞芬太尼抑制支撑喉镜诱发心血管反应的EC50为3.50 ng/ml,95%CI为3.47～3.60 ng/ml.     

国人靶控输注异丙酚的群体药代动力学

目的 运用非线性混合效应模型(NONMEM)软件计算国人异丙酚靶控输注(TCI)群体药代动力学参数并分析药代动力学特点。方法 61例行择期手术患者,ASAⅠ～Ⅱ级,男26例,女35例,年龄18～64岁,体重41～83kg。采用Tackley药代动力学参数,恒定靶血浆药物浓度(3μg·ml~(-1))变速输注60min,间断采血90min,共976个血标本,用气相色谱-质谱法测定异丙酚的血浆药物浓度。运用NONMEM软件估算异丙酚TCI群体药代动力学参数并分析药代动力学变化特点。结果 国人异丙酚TCI可用二室开放型药代动力学模型进行描述。最终药代动力学参数:K_(10)、K_(12)、K_(21)分别为0.111、0.064、0.023min~(-1);V_1、V_2分别为0.205、0.404L·kg~(-1);CL_1、CL_2分别为22.76、13.24ml·min~(-1)·kg~(-1)。最终回归模型中异丙酚血药浓度估算值与实测浓度间线性关系良好。在固定效应参数中,体重影响V_1、CL_1,年龄影响K_(21),性别对参数无影响。结论 国人异丙酚TCI的药代动力学特点为可用二室指数开放模型进行描述,中央室分布容积明显小于欧美人群,药物从中央室向外周室转运和消除速率较快。     

异丙酚靶控输注靶浓度与实测浓度的差值分析及系统性能评价

目的 分析靶控输注(TCI)异丙酚靶血浆药物浓度与实测浓度的差值,评价TCI系统性能。方法 61例下腹部择期手术患者,ASA Ⅰ～Ⅱ级。微机连接佳士比3500微量泵,选用Stelpump软件内嵌Tackley药代动力学参数。恒定靶血浆药物浓度(3μg·ml~(-1)变速输注持续1h,间断采集动脉血持续1.5h。应用气相色谱-质谱(GC-MS)法测定异丙酚血浆药物浓度。结果 异丙酚输注期间各时点的实测浓度均明显高于靶浓度,停止输注后各时点的实测浓度均明显低于靶浓度(P<0.05)。输注期间TCI系统偏离度(MDPE)为30.02％、精确度(MDAPE)为31.55％、摆动度(wobble)为21.42％、分散度(divergence)为-0.51％/h。停止输注后TCI系统偏离度为19.71％、精确度为21.63％、摆动度为13.29％、分散度为-0.26％/h。结论 国人应用TCI系统输注异丙酚,其靶血浆药物浓度与实测浓度差异明显。系统偏离度和精确度均大于TCI系统性能要求的范围,摆动度偏大。     

外科重症病人脑电双频指数指导靶控输注咪达唑仑的镇静效果

目的评价外科重症监护病房(SICU)病人脑电双频指数(BIS)指导靶控输注(TCI)咪达唑仑的镇静效果。方法SICU病人30例,随机分为3组(n=10):A组采用恒速输注咪达唑仑0．06 mg·kg-1·h-1镇静;B组采用咪达唑仑TCI镇静,初始血浆靶浓度为60 ng/ml;C组在BIS指导下咪达唑仑TCI镇静,初始血浆靶浓度为60 ng／ml。每30 min采用Ramsay镇静评分评估镇静深度,若Ramsay镇静评分小于或大于4分,则A组输注速率增加或减少0．02 mg·kg-1·h-1,B组血浆靶浓度增加或减少20 ng／ml。C组若BIS大于或小于70,则血浆靶浓度增加或减少20 ng／ml。B、C组均随机抽取30份2 ml动脉血样,测定咪达唑仑血药浓度,用偏离性和精密度评价TCI系统的性能。结果咪达唑仑TCI系统的偏离性为12．5％,精密度为22．5％。咪达唑仑实测血药浓度与Ramsay镇静评分的相关系数为0．67(P<0．05)。镇静过程中C组Ramsay镇静评分4分所占比例(54％)高于A组(28％)和B组(40％)(P<0．01)。结论咪达唑仑TCI系统的性能可靠,用于SICU病人以BIS为70调控咪达唑仑TCI,可产生良好的镇静效果。     

Target controlled infusion: TCI

Progress in computing technology has allowed the development of target controlled infusion devices, with drugs delivered to achieve specific predicted target blood drug concentrations. Target controlled infusion (TCI) system has been developed as a standardised infusion system for the administration of opioids, propofol and other anaesthetics by target controlled infusion. A set of pharmacokinetic parameters has been selected using computer simulation of a known infusion scheme. The selected model is incorporated into a computer-compatible infusion pump. Clinical trials with such systems have provided appropriate target concentrations for the administration of target controlled infusion of anaesthetic drugs. The technique of TCI strongly influences the development of intravenous anaesthesia and opens a scenario of new and exciting applications in peri-operative anaesthetic management. The launch of 'Diprifusor' as the first commercially available TCI system for propofol was the cornerstone of a successful research period within the last decade, which evaluated the pharmacokinetic foundations of computer assisted intravenous drug delivery. Nowadays TCI technology is becoming a part of routine anaesthesia technique for the practitioner rather than a research tool for specialists and those who are enthusiasts of intravenous anaesthesia. Besides clinical application in anaesthesia, target controlled systems will play a significant role as research tools in the evaluation of drug interactions in anaesthesia and in the development of new control techniques for the administration of sedative and analgesic drugs in the peri-operative period.     

依托咪酯靶控输注时靶浓度与实测血药浓度的差值分析和系统性能评价

目的分析靶控输注(TCI)依托咪酯血浆靶浓度(Cp)0.5μg/ml与实测血浆浓度(Cm)的差异,并评价内嵌Arden药代动力学参数的思路高TCI-Ⅲ型输注系统的性能。方法择期全麻下行颈椎前路或腰椎侧路减压植骨内固定术患者12例,男7例,女5例,年龄19～59岁,BMI 18～29 kg/m~2,ASAⅠ或Ⅱ级。麻醉诱导前将0.5μg/kg右美托咪定10 min恒速泵注完毕,诱导时先以舒芬太尼0.3μg/kg缓慢地静脉注射,设定依托咪酯血浆靶浓度为0.5μg/ml持续泵注,待意识消失后,静脉注入顺式阿曲库铵0.3 mg/kg,行气管插管。麻醉维持期间依托咪酯血浆靶浓度维持0.5μg/ml恒定不变,同时辅以瑞芬太尼、右美托咪定静脉泵注,维持患者BIS 40～60。于依托咪酯TCI前即刻、TCI后1、3、5、10、20、30、60、90、120 min采集桡动脉血样,采用前期试验已验证的超高效液相色谱串联质谱(UPLC-MS/MS)法测定血浆依托咪酯浓度。分析计算TCI依托咪酯的系统性能评价指标,包括精确度、偏离度、摆动度和分散度。结果 TCI后1、3、10 min时,依托咪酯Cm均明显低于Cp(P0.05),依托咪酯总体血样Cm为0.42μg/ml,明显低于Cp 16%(P0.05)。输注期间TCI系统的偏离度为-15.9%,精确度为21.9%,摆动度为22.0%,分散度为-0.72%/h。结论 TCI依托咪酯恒定靶血浆浓度(Cp)0.5μg/ml时,内嵌Arden药代动力学参数TCI系统的偏离度和摆动度稍大,但系统分散度小,能维持稳定的血浆浓度,精确度在临床可接受范围内。